Revenue
$1.22B
Fiscal year ended 2026-06-30Operating income
$251.89M
Fiscal year ended 2026-06-30Free cash flow
$263.22M
Fiscal year ended 2026-06-30BIO-TECHNE Corp (TECH) reported revenue of $1.22B for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BIO-TECHNE Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $1.22B |
| Cost of revenue | $415.97M |
| Gross profit | $799.07M |
| Operating income | $251.89M |
| Net income | Unavailable |
| Research & development | Unavailable |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $240.68M |
| Income tax expense | $58.82M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $452.42M |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | $264.71M |
| Total assets | $2.59B |
| Current assets | $744.40M |
| Total liabilities | Unavailable |
| Current liabilities | $163.70M |
| Total equity incl. NCI | $2.11B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $195.74M |
| Accounts receivable | $216.58M |
| Goodwill | $975.36M |
| Long-term debt | $200.00M |
| Accounts payable | $26.70M |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | $292.07M |
| Capital expenditures | $28.85M |
| Investing cash flow | -$18.19M |
| Financing cash flow | -$169.11M |
| Net change in cash | $102.53M |
| Stock-based compensation | $41.36M |
| Common dividends paid | $49.92M |
| Common share repurchases | $41.68M |
| Depreciation & amortization | $97.36M |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | $263.22M |
| Gross margin | 65.8% |
| Operating margin | 20.7% |
| FCF margin | 21.7% |
| SBC / revenue | 3.4% |
| Current ratio | 4.55x |
| Revenue YoY growth | -0.4% |
| Net margin | Unavailable |
| R&D / revenue | Unavailable |
| CapEx / revenue | 2.4% |
| Long-term debt / equity | 0.09x |
| Effective tax rate | 24.4% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TECH in the interactive workspace to inspect any figure back to its filing.
Source filings
10-K · Filed 2026-08-24View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-Q · Filed 2026-02-04View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-K · Filed 2025-08-22View SEC filing
10-Q · Filed 2025-05-08View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.